VANCOUVER, British Columbia and BOSTON, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc....








    



            







    
        
            December 03, 2025 08:30 ET
        

        
             | Source:
            

                Xenon Pharmaceuticals Inc.
            
                

        
    

    

    

    





        
VANCOUVER, British Columbia and BOSTON, Dec.  03, 2025  (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will host an investor webinar focused on its data presentations at the American Epilepsy Society Annual Meeting (AES 2025), including new long-term data from the ongoing X-TOLE open-label extension study of azetukalner in focal onset seizures (FOS) and real world study data on the impact of depression and burden of titration in epilepsy. The webinar will also include an update on the company’s progress preparing for commercialization of azetukalner. WebinarAzetukalner and Epilepsy Data Update: AES 2025  DateWednesday, December 10, 2025  Time10:00-11:00 AM Eastern Time  Webcast RegistrationRegister here (link)  FormatQuestions may be submitted via chat function during the live webinar or submitted in advance via email to investors@xenon-pharma.com. More information on Xenon’s AES 2025 presentations can be found here. A live webcast of the webinar will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed date and time are subject to change.  About Xenon Pharmaceuticals Inc.Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent, selective Kv7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD), and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including Kv7 and Nav1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.  Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.  Safe Harbor StatementThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995 and Canadian securities laws. These forward-looking statements are not based on historical fact, and include statements regarding the timing of and potential results from clinical studies; the potential efficacy, safety profile, future development plans in current and anticipated indications, addressable market, regulatory success and commercial potential of our and our partners’ product candidates; the efficacy of our clinical study designs; our ability to successfully develop and achieve milestones in our azetukalner and other pipeline and development programs, including the anticipated filing of INDs and NDAs; the timing and results of our interactions with regulators; our ability to successfully develop and obtain regulatory approval of azetukalner and our other product candidates; and anticipated timing of topline data readout from our clinical studies of azetukalner. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events, or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties, many of which are beyond our control, include, but are not limited to: clinical studies may not demonstrate safety and efficacy of any of our or our collaborators’ product candidates; promising results from pre-clinical development activities or early clinical study results may not be replicated in later clinical studies; our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations may be incorrect; our ongoing discovery and pre-clinical efforts may not yield additional product candidates; any of our or our collaborators’ product candidates, including azetukalner, may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; we may not achieve additional milestones in our proprietary or partnered programs; regulatory agencies may impose additional requirements or delay the initiation or completion of clinical studies; the impact of market, industry, and regulatory conditions on clinical study enrollment; the impact of competition; the impact of expanded product development and clinical activities on operating expenses; the impact of new or changing laws and regulations; the impact of unstable economic conditions in the general domestic and global economic markets; adverse conditions from geopolitical events; as well as the other risks identified in our filings with the U.S. Securities and Exchange Commission and the securities commissions in British Columbia, Alberta, and Ontario. These forward-looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.  Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.  Contact:Colleen AlabisoSenior Vice President, Corporate Affairs(617) 671-9238Media: media@xenon-pharma.comInvestors: investors@xenon-pharma.com  
            

XENE

Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025

<article>
    <header>
        <h1>Xenon Pharmaceuticals to Host Investor Webinar on Azetukalner and Epilepsy Data from AES 2025</h1>
        <p><strong>Date:</strong> December 03, 2025</p>
    </header>

    <section>
        <h2>Overview of the Upcoming Webinar</h2>
        <p>Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a biopharmaceutical company dedicated to neuroscience, has announced an investor webinar scheduled for December 10, 2025. This event will focus on data presentations from the American Epilepsy Society Annual Meeting (AES 2025), highlighting significant findings related to the ongoing development of azetukalner.</p>
        <p>The webinar will present new <strong>long-term data</strong> from the X-TOLE open-label extension study of azetukalner, specifically targeting focal onset seizures (FOS). Additionally, real-world study data will be discussed, shedding light on the <strong>impact of depression</strong> and the burden of titration in epilepsy management.</p>
    </section>

    <section>
        <h2>Webinar Details</h2>
        <p>Participants interested in this important discussion can register for the webinar details as follows:</p>
        <ul>
            <li><strong>Date:</strong> Wednesday, December 10, 2025</li>
            <li><strong>Time:</strong> 10:00 AM - 11:00 AM Eastern Time</li>
            <li><strong>Webcast Registration:</strong> [Register here (link)]</li>
            <li><strong>Format:</strong> Attendees can submit questions via the chat function during the live presentation or email them in advance to <a href="mailto:investors@xenon-pharma.com">investors@xenon-pharma.com</a>.</li>
        </ul>
        <p>A live webcast of the event will be available on the “Investors” section of Xenon's website, with a replay accessible post-event.</p>
    </section>

    <section>
        <h2>About Xenon Pharmaceuticals</h2>
        <p>Xenon Pharmaceuticals (Nasdaq: XENE) is at the forefront of drug discovery and clinical development, focusing on transformative therapeutics for neurological conditions. The company’s lead candidate, azetukalner, is a selective Kv7 potassium channel opener currently in Phase 3 trials aimed at treating epilepsy, major depressive disorder (MDD), and bipolar depression (BPD).</p>
        <p>In addition to azetukalner, Xenon is advancing a diverse early-stage portfolio featuring multiple potassium and sodium channel modulators, including Kv7 and Nav1.7 programs which are in Phase 1 for potential pain treatment. With operational bases in Vancouver, British Columbia, and Boston, Massachusetts, Xenon continues to innovate within the biopharmaceutical sector.</p>
        <p>For more details, visit <a href="http://www.xenon-pharma.com">www.xenon-pharma.com</a> or follow Xenon on LinkedIn and X.</p>
    </section>

    <section>
        <h2>Forward-Looking Statements</h2>
        <p>This announcement contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements are subject to inherent risks and uncertainties, which may cause actual results to differ materially from those projected. Key factors include clinical trial outcomes, regulatory approvals, product development milestones, and broader market conditions.</p>
        <p>Readers are advised not to place undue reliance on these forward-looking statements, as Xenon is under no obligation to update them.</p>
    </section>

    <footer>
        <h3>Contact Information</h3>
        <p>
            Colleen Alabiso<br>
            Senior Vice President, Corporate Affairs<br>
            Phone: (617) 671-9238<br>
            Media Inquiries: <a href="mailto:media@xenon-pharma.com">media@xenon-pharma.com</a><br>
            Investor Relations: <a href="mailto:investors@xenon-pharma.com">investors@xenon-pharma.com</a>
        </p>
    </footer>
</article>

Xenon hosts investor webinar on azetukalner data at AES 2025.
Webinar includes long-term data on epilepsy treatment and commercialization plans.
Azetukalner is in Phase 3 trials for epilepsy and depression disorders.
Important real-world data on epilepsy treatment burdens will be presented.
Potential for commercialization enhances Xenon's market position.

Xenon Announces Investor Webinar Highlighting Azetukalner and Epilepsy Data from AES 2025

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News